Tafamidis Meglumine Drug Asset Due Diligence Report 2026

This Tafamidis Meglumine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tafamidis Meglumine can convert its Small molecule drug profile and TTR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tafamidis Meglumine (query alias: tafamidis)
Modality / target	Small molecule drug; TTR; TTR modulators
Highest global status	Approved
Originator	Pfizer Inc.
Active developers	Pfizer Inc., Pfizer Europe MA EEIG, Pfizer Japan, Inc.

The MCP disease footprint includes Cardiomyopathies, Amyloid Neuropathies, Transthyretin Amyloid Cardiomyopathy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06940336	Phase 4	Recruiting	15	Change from Baseline Neuropathy Impairment Score-Lower Limb (NIS-LL) at Week 72
JPRN-jRCT1051250227	Not Applicable	募集中	360	治療開始後52週時点における心筋シンチグラフィ(99mTc-HMDP または99mTc-PYP) SPECT/CTによる標準化集積値(SUV)のベースラインからの変化率
DRKS00039078	Not Applicable	Recruiting	75	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Real-World Utilization Patterns, Safety, and Efficacy of Tafamidis in Patients With Hereditary Transthyretin Amyloidosis in Japan

Not Applicable; n=400; evaluation: Positive. Reported fields: ADR = 14.5 %

A PHASE 1, OPEN-LABEL, RANDOMIZED, CROSSOVER, SINGLE DOSE STUDY TO DETERMINE THE BIOEQUIVALENCE OF 12.2 MG TAFAMIDIS FREE ACID TABLETS AND COMMERCIAL 20 MG TAFAMIDIS MEGLUMINE CAPSULES ADMINISTERED UNDER FASTED CONDITIONS AND THE EFFECT OF FOOD ON ORAL BIOAVAILABILITY OF 12.2 MG TAFAMIDIS FREE ACID TABLETS IN HEALTHY ADULT PARTICIPANTS

Phase 1; n=22; evaluation: not stated. Reported fields: Pharmacokinetics(PK) Parameter - Area Under the Concentration-time Curve to Infinity (AUCinf) of PF-06291826(Geometric Mean) = 67690 Nanograms * hour per milliliter (Geometric Coefficient of Variation, 22); Pharmacokinetics(PK) Parameter - Area Under the Concentration-time Curve to Infinity (AUCinf) of PF-06291826(Geometric Mean): Ratios of Adjusted Geometric Means = 93.19(90% CI, 87.10 - 99.70); Pharmacokinetics(PK) Parameter - Area Under the Concentration-time Curve to Infinity (AUCinf) of PF-06291826(Geometric Mean): Ratios of Adjusted Geometric Means = 93.19(90% CI, 87.10 - 99.70)

A PHASE 1, OPEN-LABEL, RANDOMIZED, CROSSOVER, SINGLE DOSE STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF VARIANT 12.2 MG TAFAMIDIS FREE ACID TABLETS AND PROPOSED COMMERCIAL 12.2 MG TAFAMIDIS FREE ACID TABLETS ADMINISTERED UNDER FASTED CONDITIONS IN HEALTHY ADULT PARTICIPANTS

Phase 1; n=12; evaluation: not stated. Reported fields: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tafamidis (Both Variant 12.2 mg Tafamidis Free Acid Tablet and Proposed Commercial 12.2 mg Tafamidis Free Acid Tablet)(Geometric Mean) = 58630 hour(h)*ng/mL (Geometric Coefficient of Variation, 21); Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tafamidis (Both Variant 12.2 mg Tafamidis Free Acid Tablet and Proposed Commercial 12.2 mg Tafamidis Free Acid Tablet)(Geometric Mean): Mean differences(Test-Reference) = 98.35(90% CI, 92.92 - 104.10); Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Tafamidis (Both Variant 12.2 mg Tafamidis Free Acid Tablet and Proposed Commercial 12.2 mg Tafamidis Free Acid Tablet)(Geometric Mean): Mean differences(Test-Reference) = 98.35(90% CI, 92.92 - 104.10)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tafamidis Meglumine addresses Cardiomyopathies, Amyloid Neuropathies, Transthyretin Amyloid Cardiomyopathy. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 27 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: TTR records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-11	DKSH Enters Strategic Distribution Partnership with BridgeBio to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for ATTR-CM in Selected Asia Pacific Markets	Approved	Financial terms not disclosed
2025-11-04	Royalty Pharma Acquires Royalty Interest in Alnylam’s Amvuttra for $310 Million from Blackstone Life Sciences	Approved	US$310.0M upfront
2025-06-30	BridgeBio Pharma announced it has sold a portion of royalties due to the Company from sales of BEYONTTRA in Europe to HealthCare Royalty	Approved	US$300.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Solid dosage forms of tafamidis and its pharmaceutically acceptable salt thereof.”. The milestone feed surfaced a patent-application signal described as “Stable Solid Oral Formulation Of Tafamidis Or Pharmaceutically Acceptable Salt Thereof”. The milestone feed surfaced a patent-application signal described as “A process for the preparation of crystalline form of tafamidis”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO